NeuroPace (NPCE) EPS (Weighted Average and Diluted) Growth (3y) (2023 - 2026)
NeuroPace (NPCE) EPS (Weighted Average and Diluted) Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -6.66% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 7.81% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -1.10% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 62.43% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 10.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 61.98% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 27.51% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 6.01% |
| 10 | NeuroPace | 527.50 Mn | 473.52 Mn | 18.05 Mn | 21.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.28% |
| Dec 31, 2025 | 43.35% |
| Sep 30, 2025 | 38.80% |
| Jun 30, 2025 | 20.63% |
| Mar 31, 2025 | 23.55% |
| Dec 31, 2024 | 22.13% |
| Sep 30, 2024 | 17.63% |
| Jun 30, 2024 | 18.48% |
| Mar 31, 2024 | 78.62% |
| Dec 31, 2023 | 78.40% |
| Sep 30, 2023 | 75.59% |
| Jun 30, 2023 | 79.76% |
| Mar 31, 2023 | 76.91% |